Table 3.

Summary of CR/CRi patient characteristics

Patient no.	WHO diagnosis	Cytogenetics	Baseline WBC*	Baseline blast count	Response	Cytogenetic response?	Day of therapy at CR/CRi	Duration of CR/Cri, mo	PFS, mo	OS, mo
17	Therapy-related AML	Complex	600	0	CRc	Yes	C1D28	1	2	5
21	AML with MDS-related features	Complex	1200	20	CRi	No	C2	6	8	11
23	AML with MDS-related features†	Normal	1600	0	CR	NA	C1D28	6	7	16
25	AML without maturation	t(2;14)	1600	60	CRc	Yes	C2	13	15	16
26	Monoblastic AML (M5a)	Normal	1700	0	CRi	NA	C1D15	2	2	6
32	AML with maturation	Normal	4300	220	CR	NA	C2	≥ 15	≥ 17	≥ 17
34	AML with minimal differentiation	t(1;3)	4200	710	CRi	Yes	C1D15	≥ 17	≥ 17	≥ 17
39	Monocytic AML (M5b)	MLL abnormal	1600	0	CRc	Yes	C1D28	≥ 15	≥ 16	≥ 16
44	AML with MDS-related features	Normal	2800	30	CRi	NA	C1D28	1	2	3
45	AML with maturation	Normal	1300	0	CR	NA	C2	≥ 13	≥ 14	≥ 14

MLL indicates mixed lineage leukemia; C, cycle; D, day; and NA, not applicable.

^*WBC and blast count are shown per microliter of PB.

^†Patient 23 received 7 cycles of azacitidine for MDS ending 1 year before enrollment in the current study.